Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
CVS Health Corp (NYSE: CVS) closed the day trading at $74.09 up 1.29% from the previous closing price of $73.15. In other words, the price has increased by $1.29 from its previous closing price. On the day, 8.99 million shares were traded. CVS stock price reached its highest trading level at $74.53 during the session, while it also had its lowest trading level at $72.88.
Ratios:
For a better understanding of CVS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.66. For the most recent quarter (mrq), Quick Ratio is recorded 0.62 and its Current Ratio is at 0.80. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 0.93.
On August 14, 2025, Robert W. Baird Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $82. Leerink Partners Upgraded its Market Perform to Outperform on February 13, 2025, whereas the target price for the stock was revised from $55 to $75.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 20 ’25 when Finucane Anne A. sold 7,500 shares for $71.02 per share. The transaction valued at 532,650 led to the insider holds 22,156 shares of the business.
Finucane Anne A. bought 7,500 shares of CVS for $532,275 on Aug 20 ’25. On Jun 05 ’25, another insider, SANSONE GUY P, who serves as the Director of the company, bought 1,570 shares for $63.70 each. As a result, the insider paid 100,009 and bolstered with 12,007 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVS now has a Market Capitalization of 93970563072 and an Enterprise Value of 162693300224. As of this moment, CVS’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.67, and their Forward P/E ratio for the next fiscal year is 10.35. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.43. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.24 while its Price-to-Book (P/B) ratio in mrq is 1.21. Its current Enterprise Value per Revenue stands at 0.423 whereas that against EBITDA is 11.643.
Stock Price History:
The Beta on a monthly basis for CVS is 0.62, which has changed by 0.2494098 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, CVS has reached a high of $73.23, while it has fallen to a 52-week low of $43.56. The 50-Day Moving Average of the stock is 12.04%, while the 200-Day Moving Average is calculated to be 20.12%.
Shares Statistics:
Over the past 3-months, CVS traded about 7.38M shares per day on average, while over the past 10 days, CVS traded about 5845700 shares per day. A total of 1.27B shares are outstanding, with a floating share count of 1.27B. Insiders hold about 0.16% of the company’s shares, while institutions hold 87.67% stake in the company. Shares short for CVS as of 1755216000 were 16664640 with a Short Ratio of 2.26, compared to 1752537600 on 13670187. Therefore, it implies a Short% of Shares Outstanding of 16664640 and a Short% of Float of 1.3300001000000001.
Dividends & Splits
CVS’s forward annual dividend rate is 2.66, up from 2.66 a year ago. Against a Trailing Annual Dividend Yield of 0.036363635The stock’s 5-year Average Dividend Yield is 3.16. The current Payout Ratio is 72.76% for CVS, which recently paid a dividend on 2025-07-22 with an ex-dividend date of 2025-07-22. Stock splits for the company last occurred on 2005-06-07 when the company split stock in a 2:1 ratio.
Earnings Estimates
The market rating of CVS Health Corp (CVS) is currently shaped by the ongoing analysis conducted by 22.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.93, with high estimates of $1.05 and low estimates of $0.87.
Analysts are recommending an EPS of between $6.5 and $6.03 for the fiscal current year, implying an average EPS of $6.31. EPS for the following year is $7.15, with 27.0 analysts recommending between $7.8 and $6.49.
Revenue Estimates
15 analysts predict $98.66B in revenue for the current quarter. It ranges from a high estimate of $100.1B to a low estimate of $97.33B. As of the current estimate, CVS Health Corp’s year-ago sales were $95.43BFor the next quarter, 15 analysts are estimating revenue of $100.98B. There is a high estimate of $102.82B for the next quarter, whereas the lowest estimate is $99.58B.
A total of 19 analysts have provided revenue estimates for CVS’s current fiscal year. The highest revenue estimate was $397.34B, while the lowest revenue estimate was $390.58B, resulting in an average revenue estimate of $393.16B. In the same quarter a year ago, actual revenue was $372.81BBased on 23 analysts’ estimates, the company’s revenue will be $409.32B in the next fiscal year. The high estimate is $430.06B and the low estimate is $390.17B.
